Zymeworks Receives Orphan Drug Designation from the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Gastric Cancer

Thursday, November 19, 2020 1 min read

Key Takeaway: Zymeworks Receives Orphan Drug Designation from the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Gastric Cancer

Full Press Release Details

Zymeworks Receives Orphan Drug Designation from the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Gastric Cancer.

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

Biotech Analyst Ratings

M&A Tracker

News

Blogs

Modality Leaderboard

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

Full Press Release Details